1. Home
  2. Press release
Jul 10, 2019 13:27 JST

Source: Eisai

Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts

A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry

TOKYO, Jul 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.

(Standing from left to right) Ryan Fattman, U.S. Senator for Massachusetts; Mike Belleville, patient living with dementia; Haruo Naito, Eisai CEO; Yoshito Kishi, Morris Loeb Professor of Chemistry, Harvard University; Yasushi Nakamura, Acting Consul General at Consulate General of Japan in Boston; Mark Fuller, Undersecretary for Business Growth, Executive Office of Economic Development.
 


G2D2 integrates Eisai's strengths cultivated from human genetics, data sciences and precision chemistry for the novel drug discovery approach, and this approach will focus on the immunodementia to expand Eisai's dementia pipeline beyond amyloid-beta (A beta) and tau. Specifically, G2D2 will leverage human genetics and human biology to attempt to discover potential innovative medicines for dementia, which target the brain?s immune system.

G2D2 is located in Cambridge, Massachusetts, one of the world?s leading biotechnology clusters where academic institutions and private research organizations are concentrated, and will collaborate with the world-class science. Taking advantage of the benefits of its location, The Eisai Incubator for
NeuroDiscovery (e-IND) will provide space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics. G2D2 also plans to contribute to the development of next-generation scientific leaders in the Boston and Cambridge areas through internships, training programs and postdoctoral fellowships in genetics and drug discovery science.

With the full-scale operation of G2D2, Eisai is striving to discover innovative dementia treatments using a multi-dimensional, comprehensive approaches to fulfill unmet needs and increase the benefits for patients and their families.


About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Media Inquiries
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
 
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
 
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
 
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
 
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
 
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
 
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
 
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
March 23 2020 10:53 JST
 
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan
March 19 2020 14:15 JST
 
More Press release >>

Latest Press Release


AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST

Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST

DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST

Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST

Mitsubishi Motors Announces Production, Sales and Export Figures for April 2020
May 28, 2020 19:09 JST

Honda Sets Monthly Records for Automobile Production in China
May 28, 2020 18:52 JST

Mazda Production and Sales Results for April 2020
May 28, 2020 16:46 JST

Mazda Joins IP Open Access Declaration Against Covid-19
May 28, 2020 16:28 JST

Toyota Releases Sales, Production, and Export Results for April 2020
May 28, 2020 13:56 JST

Fujitsu Accelerates Digital Transformation with Flexible, Scale-out Software-Defined Storage ETERNUS Data Services Platform
May 28, 2020 11:26 JST

Alliance New Cooperation Business Model to Support Member-Company Competitiveness and Profitability
May 27, 2020 18:28 JST

eK X and eK Wagon Achieve Top Ratings for Preventive and Collision Safety Performance in JNCAP
May 27, 2020 15:31 JST

2019 JNCAP Assessment on Toyota Vehicles Announced
May 27, 2020 14:07 JST

Fujitsu Launches 14 New Models of Enterprise Notebooks, Tablets and Workstations Optimized for Remote Work
May 26, 2020 11:10 JST

Fujitsu Develops AI-Video Recognition Technology to Promote Hand Washing Etiquette and Hygiene in the Workplace
May 26, 2020 10:34 JST

Mitsubishi Motors Joins OPEN COVID-19 DECLARATION
May 26, 2020 09:34 JST

Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC
May 25, 2020 10:44 JST

Mazda Begins Providing, Virtual Racing Car, Mazda RX-Vision GT3 Concept Online
May 22, 2020 14:26 JST

'e5 Consortium' Established to Promote Zero-Emission Electric Vessel
May 21, 2020 15:34 JST
 More Latest Release >>